Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Investors Fund Australian Bionic Eye Company with $18 Million

publication date: Apr 4, 2017
China Huarong International Holdings together with State Path Capital BVI (which is associated with Ka-shing Li of Hong Kong's CK Hutchison) have invested $18 million in Australia's Bionic Vision Technologies (BVT). BVT is developing a bionic eye that consists of an external camera, located on a glasses frame, and a retinal implant. With the new funds, the company will manufacture devices and begin a clinical trial of the device in patients with an inherited degenerative eye condition known as retinitis pigmentosa. Located in Melbourne, BVT is privately owned and includes staff from several Australian universities. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital